\n \nDescription \nCefuroxime is a well-characterized and effective antibacterial agent, which has broad-spectrum bactericidal activity against a wide range of common pathogens, including Beta-lactamase producing strains. Cefuroxime has good stability to bacterial Beta-lactamase and consequently, is active against many Ampicillin-resistant and Amoxicillin-resistant strains. Clavulanic Acid has a similar structure to the beta-lactam antibiotics but binds irreversibly to the beta-lactamase enzymes. The presence of Clavulanic Acid in Famiclav formulations protects Cefuroxime from degradation by beta-lactamase enzymes and effectively extends the antibacterial spectrum of Cefuroxime to include many bacteria normally resistant to Cefuroxime and other cephalosporins. \n \nComposition \nFamiclav 250?Tablet :?Each film-coated tablet contains Cefuroxime 250 mg as Cefuroxime Axetil USP and Clavulanic acid 62.50 mg as diluted Potassium Clavulanate BP. \nFamiclav 500?Tablet :?Each film-coated tablet contains Cefuroxime 500 mg as Cefuroxime Axetil USP and Clavulanic acid 125 mg as diluted Potassium Clavulanate BP. \nFamiclav Powder for Suspension: After reconstitution, each 5 ml suspension contains Cefuroxime 125 mg as Cefuroxime Axetil USP and Clavulanic acid 31.25 mg as diluted Potassium Clavulanate BP. \n \nIndications \n? Upper respiratory tract infections: Ear, nose and throat infections such as otitis media, sinusitis, tonsillitis?and?pharyngitis. \n? Lower respiratory tract?infection :?Acute bronchitis, acute exacerbations of chronic bronchitis and pneumonia. \n? Skin and soft tissue?infections :?Furunculosis, pyoderma?and?impetigo. \n? Genito-urinary tract infections: Pyelonephritis, urethritis?and?cystitis. \n??Gonorrhoea: Acute uncomplicated gonococcal urethritis and cervicitis. \n? Early Lyme Disease and subsequent prevention of late Lyme Disease \nOR AS DIRECTED BY THE PHYSICIAN. \n \n